scholarly journals Spontaneously ruptured hepatocellular carcinoma in Fontan-associated liver disease: A case report

2020 ◽  
Vol 8 ◽  
pp. 2050313X2092203
Author(s):  
Takahiro Kubo ◽  
Yosuke Aihara ◽  
Hideto Kawaratani ◽  
Tadashi Namisaki ◽  
Ryuichi Noguchi ◽  
...  

The prognosis of congenital heart disease is dramatically improved by cardiac surgery. The Fontan procedure is the definitive palliative operation for patients with single-ventricle physiology. In parallel with the longer survival time achieved with the Fontan procedure, the incidence of Fontan-associated liver disease is increasing. A 40-year-old man who underwent Fontan procedures at the ages of 9 was referred to our hospital for further evaluation of multiple hepatic tumors. Enhanced computed tomography showed large hepatocellular carcinomas with portal thrombi (Vp3). Spontaneous hepatocellular carcinoma rupture occurred 2 weeks after the first visit to our hospital, and emergent transcatheter arterial embolization of the hepatic artery was performed. Three months later, the patient died of liver failure. Autopsy findings showed moderately differentiated hepatocellular carcinoma with a cirrhotic liver characterized by centrilobular fibrosis and sinusoidal dilation similar to that in Fontan-associated liver disease. We reported the first case of spontaneously ruptured hepatocellular carcinoma treated by emergent transcatheter arterial embolization in Fontan-associated liver disease. As the early diagnosis of liver cirrhosis and hepatocellular carcinoma results in better patients’ outcome, cardiologists and hepatologists should be aware of Fontan-associated liver disease and advise patients to have regular follow-up of the liver.

1993 ◽  
Vol 34 (1) ◽  
pp. 26-29 ◽  
Author(s):  
S. Savastano ◽  
G. P. Feltrin ◽  
D. Neri ◽  
P. da Pian ◽  
M. Chiesura-Corona ◽  
...  

Thirty-three consecutive patients with previously untreated hepatocellular carcinoma (HCC) and 6 patients with recurrent HCC were treated with transcatheter arterial embolization (TAE). The patients were not eligible for surgical resection or percutaneous ethanol injection. TAE was performed with Lipiodol Ultra-Fluid, epidoxorubicin and Gelfoam, with a mean of 1.7 treatments per patient. CT was performed 15 days after TAE. The mean cumulative survival was 14.2 months in patients with previously untreated HCC. The survival of patients stages Okuda I and II did not differ significantly (p > 0.05); tumor size did not affect survival (p > 0.05). Two patients with recurrent HCC died 7.0 and 9.3 months after the diagnosis of tumor recurrence; the remaining 4 patients are still alive with a maximum follow-up of 22.5 months from the diagnosis of HCC recurrence. Ten complications occurred in 8 patients, and were controlled by medical therapy. Eleven patients died during the study; no death was related to TAE. The series was not randomized, but comparison with the natural history of HCC suggests that TAE is effective as palliative treatment of advanced or recurrent HCC.


1984 ◽  
Vol 29 (12) ◽  
pp. 1137-1141 ◽  
Author(s):  
Toshihiko Nouchi ◽  
Masanobu Nishimura ◽  
Manabu Maeda ◽  
Testutaro Funatsu ◽  
Yasushi Hasumura ◽  
...  

Kanzo ◽  
1986 ◽  
Vol 27 (8) ◽  
pp. 1094-1104
Author(s):  
Eiji OYAKE ◽  
Mikio KARIYA ◽  
Kazuaki CHAYAMA ◽  
Sousuke CHIHARA ◽  
Yasuyuki TAKAHASHI ◽  
...  

Surgery ◽  
1998 ◽  
Vol 124 (3) ◽  
pp. 526-535 ◽  
Author(s):  
Ryo Shimada ◽  
Hiroshi Imamura ◽  
Masatoshi Makuuchi ◽  
Junpei Soeda ◽  
Akira Kobayashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document